Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients.
Human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica.
Capture, crawl, cross: the T cell code to breach the blood-brain barriers.
Glial contributions to neural function and disease.
Discovery of peptoid ligands for anti-aquaporin 4 antibodies.
Exome sequencing in single cells from the cerebrospinal fluid in multiple sclerosis.
A practical guide to the treatment of neuromyelitis optica.
Homophilic interaction of the L1 family of cell adhesion molecules.
Sleep-disordered breathing in multiple sclerosis.
The occurrence of dystonia in upper-limb multiple sclerosis tremor.
Microglia Induce Neurotoxic IL-17+ γδ T Cells Dependent on TLR2, TLR4, and TLR9 Activation.
Anti-JC virus seroprevalence in a Finnish MS cohort.
Accelerated repair of demyelinated CNS lesions in the absence of non-muscle myosin IIB.
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes.
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Right Under Our Noses: Olfactory Pathology In Central Nervous System Demyelinating Diseases
Periventricular Demyelination and Axonal Pathology Is Associated with Subependymal Virus Spread in a Murine Model for Multiple Sclerosis.
Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration.
Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden.
Tremor reduction and quality of life after deep brain stimulation for multiple sclerosis-associated tremor.
Impact of diagnosis and early treatment on the course of multiple sclerosis.
Consensus statements from a panel of u.s. Managed care pharmacists and physicians for management of multiple sclerosis agents.
In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice.
Pages
« first
‹ previous
…
187
188
189
190
191
192
193
194
195
…
next ›
last »